Catalogue of ischemic injury factors

Epistemic status: each individual mechanism is well-documented (C1–C2). The specific "19 factors" count is probably a heuristic Aurelia uses rather than a published list; I can't find a paper that enumerates exactly 19. But the literature easily supports 20+ partially independent factors, which is the substantive point. The "nobody controls them all" claim is obviously true clinically.

Why this matters for cryopreservation

Every one of these mechanisms is racing to damage neural tissue the moment perfusion stops. The preservation window is not a single number — it's the envelope inside which enough of these processes can be stalled, reversed, or locked in place by fixation. Understanding which factors matter at which time scale tells you what you can and can't mitigate.

For cryopreservation specifically, we need to distinguish:

• Factors that are reversible given fast enough re-perfusion (don't need to worry about these if you fix tissue quickly).
• Factors that lock in rapidly and are irreversible even with perfusion (you have to beat these).
• Factors that only manifest during reperfusion itself (ASC's glutaraldehyde step arguably prevents these because it's not metabolic reperfusion).

Master list

Numbering is loose; most of these interact and overlap.

Energy failure and ionic derangement

1. ATP depletion. Brain has ~30 s of ATP reserve. Oxygen failure → oxidative phosphorylation stops → glycolysis alone can sustain only a small fraction of demand. ATP half-life in anoxia: ~2–5 min for detectable loss, complete by ~10 min. (Wikipedia ischemic cascade; Siesjö 1988, PubMed 2823355)
2. Na+/K+-ATPase failure. Without ATP, the main ion pump fails. Na+ floods in, K+ leaks out. Depolarization.
3. Anaerobic glycolysis and acidosis. Lactate accumulates; intracellular pH drops to ~6.2 from ~7.2 within minutes. Acidosis worsens mitochondrial damage and activates acid-sensing ion channels.
4. Calcium influx / calcium overload. NMDA-receptor opening (see #6) plus voltage-gated Ca²⁺ channels → massive Ca²⁺ load → activates calpains, phospholipases, endonucleases (PMC12985473, 2026).

Excitotoxicity

5. Glutamate release. Depolarization + reversed EAAT transporters dump glutamate into the extracellular space. Levels can reach ~100× normal.
6. NMDA / AMPA receptor overactivation. Drives more Ca²⁺ influx. Also drives iron influx via DMT1/Dexras1 pathway — a ferroptosis bridge.
7. Zinc translocation. Synaptically released Zn²⁺ enters neurons through NMDA channels, triggering additional death pathways.

Cell death pathways

8. Necrosis. Immediate / core-infarct death.
9. Apoptosis. Calpain activation → caspase cascade; cytochrome c release from mitochondria. Acts over hours–days in the penumbra.
10. Necroptosis. RIPK1/RIPK3-dependent programmed necrosis; relevant in penumbra.
11. Ferroptosis. Iron-dependent lipid peroxidation; GPX4 inactivation; system Xc− inhibition. Particularly active in ischemic stroke penumbra (Frontiers Pharmacology 2022).
12. PANoptosis (pyroptosis + apoptosis + necroptosis integrated cell death). Recent framing, ischemia–reperfusion context (Frontiers Cellular Neuroscience 2023).
13. Autophagy dysregulation. Can be protective early, lethal late.

Oxidative damage

14. Reactive oxygen species (ROS). Superoxide, hydrogen peroxide, hydroxyl radical. Mitochondrial sources (complex I, III), xanthine oxidase, NADPH oxidase, uncoupled NOS.
15. Lipid peroxidation. Membranes degraded; breakdown products propagate damage. Substrate for ferroptosis.
16. Protein oxidation / nitration. 3-nitrotyrosine, carbonyls. Particularly damaging to synaptic proteins.
17. DNA damage. Single- and double-strand breaks; oxidized bases. PARP activation consumes NAD+, worsens energy crisis.

Organelle failure

18. Mitochondrial permeability transition pore (mPTP) opening. Triggered by Ca²⁺ + ROS; collapses mitochondrial membrane potential; releases cytochrome c; triggers apoptosis.
19. ER stress / unfolded protein response. Calcium store depletion + oxidative stress → ER stress → apoptosis amplification.
20. Lysosomal permeabilization. Releases cathepsins into cytosol.

Inflammation and immune involvement

21. Microglial activation. Resident immune cells become activated minutes to hours; release cytokines, ROS, glutamate.
22. Leukocyte infiltration. Neutrophils arrive first (hours), monocytes later; neutrophils plug capillaries (see #29).
23. Complement activation. Classical + alternative pathways; membrane attack complex; opsonization.
24. Mast cell degranulation. Rapid release of histamine, proteases → vasogenic edema.
25. DAMPs / cytokine storms. HMGB1, IL-1β, TNFα. Propagate injury to penumbra.

Vascular and microcirculatory failure

26. No-reflow phenomenon. Capillaries that don't re-perfuse after arterial opening. Mechanism below.
27. Pericyte contraction and death-in-rigor. Pericytes clamp down on capillaries, then die in the constricted state (Hall 2014, PubMed 24670647).
28. Endothelial and astrocyte end-foot swelling (cytotoxic edema compressing capillaries). (Stokum 2016)
29. Neutrophil capillary plugging. 20–30% of distal capillaries blocked (El Amki 2020).
30. Platelet aggregation and microthrombi.
31. RBC trapping in constricted capillaries.
32. Blood-brain barrier breakdown. Tight junction degradation by calpain, MMP-9. Leads to vasogenic edema.
33. Vasogenic edema. Serum protein extravasation → extracellular water accumulation → mass effect + ICP rise.

Reperfusion-specific injury

34. ROS burst at reoxygenation. Xanthine oxidase-catalyzed superoxide flood; mitochondrial Ca²⁺/ROS burst.
35. Hemorrhagic transformation. Reperfusion into damaged BBB → bleeding.
36. Secondary ischemia from reperfusion injury. Inflammatory cascades re-compress vessels.

Structural and osmotic

37. Cytoskeletal breakdown. Calpain cleaves spectrin and tau; synaptic proteins unravel.
38. Membrane bleb formation. Ca²⁺-driven cytoskeletal detachment.
39. Proteolytic autolysis. Lysosomal/mitochondrial proteases released; self-digestion begins within tens of minutes.

Secondary complications relevant to preservation

40. Spreading depolarizations. Slow waves of depolarization propagating 2–5 mm/min; consume ATP; expand the infarct penumbra.
41. Glymphatic failure. Perivascular clearance stops; metabolic waste accumulates.
42. Endothelial glycocalyx shedding. Loss of the protective polysaccharide layer → increased permeability.

Time-scale summary

Approximate wall-clock of each factor in a normothermic ischemic brain:

What's controllable clinically

• Hypothermia (see 06-cooling-physics.md): broadly slows almost everything. Gold-standard clinical neuroprotectant. Q10 ≈ 2–3 for most metabolic processes; up to 12 for some enzymatic steps in the 30–38 °C range.
• Targeted pharmacology: tried, mostly failed. NMDA antagonists (selfotel, aptiganel), free-radical scavengers (tirilazad, NXY-059), Ca²⁺ channel blockers, magnesium — all mostly disappointed in trials. The humbling lesson is that individual-mechanism targeting doesn't work when 40 things are going wrong in parallel.
• Thrombolysis / thrombectomy: restores flow if the problem is a proximal clot. Doesn't help global ischemia after cardiac arrest.
• Neutrophil depletion (experimental): Anti-Ly6G restores microvascular perfusion in mouse stroke (El Amki 2020) but has not translated to clinical use.
• Glucose control: hyperglycemia worsens outcomes.
• MAP support: keep perfusion pressure up to the extent the brain can handle.

What's uncontrollable pre-mortem (in the cryopreservation context)

Crucially, in the Nectome MAiD context:

• You can premedicate with heparin (prevent microthrombi).
• You can plan the arrest so that washout begins fast.
• You cannot easily intervene pharmacologically on most of the cascade because the patient isn't yet under arrest.
• You cannot pre-cool the brain meaningfully through skin (see 06-cooling-physics.md).

Aurelia's "~19 factors, nobody controls them all" is entirely right in spirit: the list is long, the interactions are brutal, and the clinical record of single-mechanism targeting is discouraging. The ASC answer — stop the clock with aldehyde fixation — is an end-run around having to catalog-and-inhibit each factor individually. You don't need to stop excitotoxicity, ferroptosis, calpain activation separately; you just need to cross-link proteins and stabilize membranes before those processes have finished.

Why aldehyde fixation pre-empts most of the cascade

Glutaraldehyde at 2–4% concentration cross-links free amine groups on proteins within 10–60 seconds of tissue contact (McIntyre & Fahy 2015). Once a protein is cross-linked into a stable polymer matrix, it cannot be cleaved by calpain, cannot be denatured by free radicals, and the cell containing it cannot execute apoptosis. Membranes are stabilized against osmotic stress. Organelles stay in place.

What fixation doesn't do:

• Repair damage that has already happened pre-fixation (ATP-depletion artifacts in cell-body granularity, mitochondrial cristae damage that occurred in the first 10 minutes).
• Help if the fixative can't reach the tissue (hence: the capillary problem).

This is why the quality ceiling of ASC is set by the ischemic interval before perfusion plus the quality of the perfusion bed itself — not by anything downstream of fixation. Getting from N factors back to "capillary diameter × time" as the primary lever is precisely the ASC architectural insight.

Summary

• The ischemic cascade involves dozens of partially independent mechanisms.
• Clinical neuroprotection attempting to block individual mechanisms has a poor record.
• Hypothermia is a broad-spectrum rate-reducer; effectiveness is bounded by how fast you can cool the brain.
• Aldehyde fixation is a fundamentally different strategy: don't block each mechanism, just freeze all chemistry at once.
• For ASC, the race against the cascade resolves to a single operational variable: get fixative into the capillaries before they close. Everything else is subsidiary to this.